New Products In Brief

Stryker Corp. commences global launch of its next-generation Trevo ProVue stent-based clot retrieval device, the company announced Nov. 8. Designed to treat acute ischemic stroke, the 510(k)-cleared device is the first thrombus-removing system fully visible during the procedure for precise positioning within the clot and optimized clot retrieval, according to the firm. While previous technology only provided visibility of the edges of the devices, Stryker says, platinum has been added along the length of the Trevo ProVue, making it fully visible. “Physicians are able to visualize the deployment and accurate placement of the device, how it interacts with the clot, and see its retrieval from start to finish,” a spokesperson told “The Gray Sheet.” The device is supported by clinical evidence from Stryker’s TREVO and TREVO 2 clinical trials, showing high revascularization and improved clinical outcomes compared to the first-generation Merci Retriever. Stryker gained the Trevo technology through its 2011 acquisition of Concentric Medical. (See Also see "Stryker Buys Concentric Medical To Enter Acute Ischemic Stroke Market" - Medtech Insight, 5 September, 2011..)

The Trevo ProVue is fully visible during clot retrieval procedures, allowing for precise positioning during treatment of patients experiencing acute ischemic stroke.